Eli Lilly plans to submit tirzepatide application at the end of the year

After presenting new results from a comparison study between Eli Lilly's tirzepatide and diabetes drug Lantus, the company is ready to set a time horizon for when it will seek approval for the drug (Updated).
Photo: Mike Segar/Reuters/Ritzau Scanpix
Photo: Mike Segar/Reuters/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

A recent study conducted by Eli Lilly shows positive effects of the use of diabetes drug tirzepatide.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading